-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: X

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Xanthopoulos, C.
2859 - Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
Xao, W.
2637 - Hodgkin Lymphoma Variant of Richter Transformation: Morphology, EBV Status, Clonality and Survival Analysis a Retrospective Study of 77 Patients
Xavier, E.
3203 - Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working Party-EBMT Study
Xavier-Ferrucio, J. M.
3601 - CXCR7 Participates in Chemotaxis and Homing Mediated By CXCL12
Xavy, S.
841 - Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation 
Xenakis, J.
3117 - Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306
3783 - Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605
Xenocostas, A.
3346 - Erythropoietin in Elderly Patients with Anemia of Unknown Etiology
Xi, H.
1855 - Macrofocal Multple Myeloma Is a Particular Subgroup of Multiple Myeloma
Xi, R.
2378 - Polycomb Repressive Complex 1 Enhances HSC Self-Renewal through Repressing the Canonical Wnt Signaling Pathway
Xia, D.
3910 - Systematic Analysis of Cell-of-Origin, Sequencing and Genomic Imbalances Identifies a Distinct Subset of Rituximab Treated Diffuse Large B-Cell Lymphoma with an Inferior Survival
Xia, L. H.
4505 - Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China
Xia, Y.
974 - Sustained Elevation of Adenosine-ADORA2B Signaling Promotes Chronic Pain through Neuro-Immune Interaction in Sickle Cell Disease
2134 - Metabolomic Profiling Identifies Hypoxia-Induced Imbalanced Lands' Cycle Promotes Sickling and Disease Progression
Xia, Z.
1521 - Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma
3936 - Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience
Xia, Z.
1458 - Predictive Value of Interim 18f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study
2690 - RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog
3956 - A Prospective, Self-Controlled and Randomized Study about the Optimal Timing of Leucovorin Rescue after High Dose Methotrexate Management
Xian, L.
2466 - A Novel Feed-Forward Loop Involving the High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein and cMYC in Acute Myeloid Leukemia Is Targeted By JQ1
Xiang, P.
855 - Mesenchymal Stem Cell As a Salvage Treatment for Patients with Refractory Bronchiolitis Obliterans Syndrome after Allogenetic Hematopoietic Stem Cell Transplantation
Xiao, D. Y.
2088 - Treatment-Related Weight Change and Overall Survival in United States Veterans with Follicular Lymphoma
Xiao, G.
1875 - Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation
Xiao, G.
556 - Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia
1434 - CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia
Xiao, H.
1238 - Restoration of CCAAT Enhancer Binding Protein Alpha P42 Overcomes Myeloid Differentiation Block and All-Trans Retinoic Acid Resistance in Human Acute Promyelocytic Leukemia NB4-R1 Cells
3130 - Excellent Therapeutic Results Achieved in Salvage Therapy for Steroid-Refractory Grades III-IV Acute Gvhd with Basiliximab and Etanercept : A Multicenter Prospective Study
Xiao, J.
4418 - AAV3 Capsid Is Superior for In Vivo Gene Transfer to Human Hepatocytes Compared to Serotypes 5 and 8 in a Mouse/Human Chimeric Model
Xiao, L.
3775 - Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO
Xiao, L.
1300 - Clinical Significance of Co-Existence of PHF6 and NOTCH1 mutations in Adult T-Cell Acute Lymphoblastic Leukemia
Xiao, P.
2398 - Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia
Xiao, S.
637 - Production of BMP4 By Endothelial Cells Is Crucial for Endogenous Thymic Regeneration
Xiao, V.
2793 - Development of Xpert® BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale
Xiao, W.
2038 - The Light Chain of Rat Factor VIII Confers Its Superior Cofactor Activity
4420 - Identification of Activity Enhancement Residue of Human FVIII and Novel Factor VIII Variant for Human Gene Therapy
Xiao, Y.
645 - A Common Progenitor for Macrophages, Osteoclasts and Dendritic Cells Newly Discovered in Human Bone Marrow and Cord Blood Yields Dendritic Cells with T-Cell Priming Ability
Xiao, Y.
1600 - Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study
Xiao, Z.
4073 - Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)
Xiao, Z.
303 - HIF-1a Pathway, As a Signal Funnel for Genetic, Epigenetic, and Metabolic Aberrations, Is Sufficient and Essential for MDS Development
931 - Activation of HIF-2a-EPO Axis in Kidney or Liver Is Sufficient to Drive Erythrocytosis in a Novel Inducible HIF-2a Transgenic Mouse Model
2835 - A Novel Erythroid Regulator MLF1IP Promotes Proliferation in Mice By Regulating Cell Cycle
2874 - Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome
2876 - Impact of Megakaryocyte Morphology on Prognosis of Persons with Myelodysplastic Syndromes
4080 - Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs
Xiao-Xuan, W.
3555 - Annexin A5 Resistance Is Associated with Thrombotic Risk in Patients with the Lupus Anticoagulant: The Vienna Lupus Anticoagulant and Thrombosis Study (LATS)
Xiaoli, L.
2439 - CDKN2 Gene Deletion Impair Prognosis in  Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era
4036 - Therapeutic Immune Monitoring of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Focus on CD4+CD25+t Cells
Xiaoyan, J.
4012 - Identification of a New AHI-1-Mediated-PP2A-Beta-Catenin-BCR-ABL-JAK2 Complex Modulating Resistance of CML Stem/Progenitor Cells to Tyrosine Kinase Inhibitors
Xicoy, B.
608 - The Complete Mutatome and Clonal Architecture of Del(5q)
1682 - Methylation Patterns in Patients with High-Risk Myelodysplatic Syndromes and Secondary Acute Myeloid Leukemia Treated with Azacitidine (high-risk MDS 2009 protocol from CETLAM Group)
2883 - Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features
2905 - Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol from CETLAM Group)
4015 - Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression
Xie, C.
1265 - Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells
Xie, H.
3104 - Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation Is Frequent and Persistent
Xie, H.
4112 - Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression
Xie, J.
3496 - Antibody Engineering of Anti-TFPI Bypass Therapeutic BAY 1093884: Isotype Selection and Sequence Optimization
Xie, J.
1378 - KBP-1 Supports Acute Myeloid Leukemia Development
Xie, J.
707 - Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Xie, J.
1103 - Patterns of Prior Treatment and Bleeds Among Patients with Severe Hemophilia a: Impact on Frequency of Dosing with Bay 81-8973 in the Leopold I Trial
Xie, L.
745 - Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
Xie, L.
3239 - Human Factor VIII Expression and Normalization of Bleeding Following AAV Gene Therapy in a Double Knockout Mouse Model of Hemophilia
Xie, X. Q.
1796 - p62-ZZ Domain Inhibition Prevents MM Cell-Induced Epigenetic Changes at the Runx2 and C/EBPb Promoters
Xie, Y.
2960 - A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma
Xie, Y.
1157 - Developmental Stage and Sex-Specific Role of IGF/IGF1R Signaling in Hematopoietic Stem and Progenitor Cells
Xie, Z.
1743 - Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia
Xie, Z.
3851 - Toward Individualized Therapy: Correlation of Mutation Analysis with in Vitro high Throughput Drug Sensitivity Testing in New Diagnosis and Relapsed Acute Myeloid Leukemia
Xilin, C.
210 - Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor
Xin, G.
284 - Kras Is Critical for CD8 T Cell Antiviral Function
Xin Victoria, W.
795 - in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993
Xing, P.
2718 - Treatment Outcome and Prognostic Model for Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study in a Cohort of 305 Patients with Long Term Follow-up
Xing, R.
2874 - Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome
Xing, W.
3599 - Cell Autonomous Defects of Mesenchymal Stem Progenitor Cells of Patients with CMML Contribute to Impaired Hematopoietic Supportive Activity
Xing, Y.
2144 - Chronic Iron Overload Damage the Erythropoiesis in MDS Mouse By Increasing GDF11 and ROS Levels
Xinyu, N.
3782 - Leukapheresis Reduces 4-Week Mortality in Leukemia Patient with Hyperleukocytosis-a Retrospective Study from a Tertiary Center
Xiong, J.
698 - PCYT1A in MYC-Driven Lymphoma: Role on Aberrant Choline Metabolism and Therapeutic Targeting By Berberine
Xiong, M.
3217 - Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
3224 - Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases
Xiong, W.
1725 - Intratumoral Genetic Heterogeneity Provides Additional Prognostic Significance of the CLL Genomic Features
3879 - Different Prognostic Significance of a Panel Cytogenetic Aberrations Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders
Xiu, Y.
2367 - Enhanced NF-Kb Non-Canonical Signaling Impairs Hematopoietic Stem Cell Self-Renewal
Xochelli, A.
1464 - Auto-Immune Origin of B Cells from HCV-Associated Lymphoma
1479 - Unique Versus Common: Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations
2485 - An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL
2921 - Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?
Xu, C.
2359 - ER71/ETV2 Is Essential for Hematopoietic Regeneration after Injury
Xu, C.
279 - Targeting Neutrophil Aging and the Microbiota for the Treatment of Sickle Cell Disease
Xu, D.
1302 - Comparison of the Efficacy of the First and Second-Generation Tyrosine Kinase Inhibitors in the First-Line Treatment of Ph-Positive Acute Lymphoblastic Leukemia
Xu, F.
1651 - DHX9 Mutations Are Identified As a Novel Recurrent Event in Patients with Myelodysplastic Syndromes and Closely Related to Bone Marrow Failure
1660 - EZH2-Mediated Activation of Serine Biosynthetic Pathway Is Critical for Resistance of Clonal Cells to Stress-Related Apoptosis in Low-Grade Myelodysplastic Syndrome
1689 - A Primary Study of the Gene Mutations in Predicting Treatment Response to Decitabine in Patients with MDS
Xu, H.
714 - MSI2 Is Required for Maintaining the Activated Myelodysplastic Syndrome Stem Cell
Xu, H.
1572 - USP47 Is a New Target in Chronic Myelogenous Leukemia
Xu, H.
839 - Drug Resistant Myeloma Cells Cause More Severe Bone Destruction in Myeloma
1804 - Targeting Neddylation to Overcome Drug Resistance in Multiple Myeloma
Xu, H.
986 - Characteristics and Potential Biomarkers for Chronic Pain in Patients with Sickle Cell Disease
Xu, J.
2 - The LRF/ZBTB7A Transcription Factor Is a BCL11A-Independent Repressor of Fetal Hemoglobin
47 - Quantitative Proteomic and Transcriptomic Analysis Reveals Post-Transcriptional Regulation of Mitochondrial Biogenesis during Erythropoiesis
Xu, J.
3909 - MYC/BCL2 Double Hit Lymphoma: What Really Matters
Xu, J.
723 - Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways
Xu, J.
464 - B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal Center B-Cell Subtype, Plus Self Antigen-Induced in the Activated B-Cell Subtype
Xu, J.
930 - Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Xu, J.
4073 - Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)
4080 - Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs
Xu, K.
1184 - Podocalyxin Negatively Regulates Stress Myelopoiesis, Directly Binds Rap-1A and Modulates Its G-CSF-Induced Activity
Xu, L.
880 - Cardiovascular Disease in Adolescents and Young Adults with Hematologic Malignancies
Xu, L.
1462 - Analysis of Programmed Death Ligand 1 (PD-L1) Expression in Diffuse Large B Cell Lymphomas (DLBCL) in HIV-Negative Versus HIV-Positive Patients
Xu, L.
62 - Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors
1970 - Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Might Overcome the Adverse Effect of Minimal Residue Disease Pretransplant in Patients with Standard-Risk Acute Myeloid Leukemia
2006 - CTLA-4 Polymorphisms and Haplotype Correlate with Survival and aGVHD after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor
Xu, L.
44 - Modular Domains within a Super Enhancer Determine Drug Resistance in Leukemia
Xu, L.
128 - Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia
705 - HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma
1486 - The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability
1563 - Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia
2665 - Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88
4004 - Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia
Xu, L.
3719 - Synergistic Targeting of Protein Translation and Inhibition of NOTCH Signaling in T-ALL
Xu, M.
12 - Platelet GPIba Is Important for Thrombopoietin Production and Thrombopoietin-Induced Platelet Generation
Xu, M.
913 - Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs
4100 - Efficient Engraftment and Disease Replication of Myelodysplastic Syndromes Using a Novel Humanized Mice Model
Xu, M.
775 - Novel Functional Roles for Ten-Eleven-Translocation 2 (Tet2) in Normal and Leukemic Growth of Mast Cells
1224 - Cooperative Effect of Haploinsufficient ASXL1 and NF1 in Acute Myeloid Leukemia Transformation
1607 - Survival and Prognosis of Chinese Patients with Post-Polycythemia Vera Myelofibrosis
3599 - Cell Autonomous Defects of Mesenchymal Stem Progenitor Cells of Patients with CMML Contribute to Impaired Hematopoietic Supportive Activity
3644 - ASXL1 Is a Key Regulator for Erythroid Development and Asxl1 Loss Impairs Erythropoiesis In Vivo
3650 - Combined Loss of Tet1 and Tet2 Promotes B-Cell, but Not Myeloid Malignancies in Mice
Xu, N.
2439 - CDKN2 Gene Deletion Impair Prognosis in  Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era
4036 - Therapeutic Immune Monitoring of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Focus on CD4+CD25+t Cells
Xu, P.
2733 - Additional Two Cycles of Rituximab Improves the Prognosis of Low-Risk NCCN-IPI Diffuse Large B-Cell Lymphoma Patients Responded to R-CHOP Regimen
Xu, Q.
323 - Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
2509 - Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial
Xu, R.
3763 - Megakaryocytes Support Viability Proliferation and Protection of Primary Pre-B ALL Cells from Chemotherapy
Xu, S.
44 - Modular Domains within a Super Enhancer Determine Drug Resistance in Leukemia
Xu, T.
3227 - Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Severe Aplastic Anemia
4381 - Frontline Allogeneic and Autologous Hematopoietic Cell Transplant for Peripheral T-Cell Lymphomas (PTCLs): A Comparison Study Between Conventional Chemotherapy and Hematopoietic Cell Transplant from a Chinese Center
Xu, W.
1473 - Prognostic Significance of Bone Marrow Infiltration Detected By PET-CT in Newly Diagnosed Diffuse Large B Cell Lymphoma
3895 - The Distinct Clinical Features and Prognosis of the CD10+MUM1+ and CD10-Bcl6-MUM1- Diffuse Large B-Cell Lymphoma
3918 - The Prognostic Value of Whole-Body Suvmax of Nodal and Extranodal Lesions Detected By 18F-FDG PET-CT in Patients with Extranodal NK/T-Cell Lymphoma
4148 - Differential Diagnosis of Lymphoid Enhancer-Binding Factor 1 Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders
Xu, W.
2082 - Cost Comparison of Hematopoietic Stem Cell Transplantation and Conventional Therapy for Patients with Thalassemia Major in China
Xu, X.
2887 - Targeted Detection of Copy Number Variants Using a Myeloid Malignancy Next Generation Sequencing Mutation Panel Allows Comprehensive Genetic Analysis Using a Single Testing Method
Xu, X. S.
4222 - Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis
4254 - Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective
Xu, Y.
1784 - Clonal Evolution Paths Significantly Impact the Outcome of Myeloma
2480 - Suppression of Cdc37 Induces Bortezomib Resistance through Autophagy Activation and Plasma Cell Immaturation in Multiple Myeloma
4186 - Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis
Xu, Y.
1394 - Exome Sequencing Identifies Highly Recurrent Somatic GATA2 and CEBPA Mutations in Acute Erythroid Leukemia
Xu, Y.
3500 - Acute Efficacy of a Novel Anti-Tissue Factor Pathway Inhibitor Antibody BAY 1093884 in Hemophilia A Mouse Severe Tail Bleeding
Xu, Y.
3268 - Incidence of Major Hemorrhage Among CLL and MCL Patients Compared to the General Elderly Population: An Analysis of the US SEER-Medicare Linked Database
Xu, Y.
2822 - Clinicopathologic Analysis of Calr Mutation Subtypes in Myeloproliferative Neoplasms
Xu, Y.
2611 - Clinical Utility of Next-Generation Sequencing-Based Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Xu, Y.
1250 - The Deubiquitylase Usp22 Is Important for KRAS-Driven Myeloproliferative Disease
Xu, Z.
303 - HIF-1a Pathway, As a Signal Funnel for Genetic, Epigenetic, and Metabolic Aberrations, Is Sufficient and Essential for MDS Development
931 - Activation of HIF-2a-EPO Axis in Kidney or Liver Is Sufficient to Drive Erythrocytosis in a Novel Inducible HIF-2a Transgenic Mouse Model
2835 - A Novel Erythroid Regulator MLF1IP Promotes Proliferation in Mice By Regulating Cell Cycle
2874 - Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome
2876 - Impact of Megakaryocyte Morphology on Prognosis of Persons with Myelodysplastic Syndromes
4073 - Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)
4080 - Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs
Xuan, L.
4352 - Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study
Xuan, Z.
3903 - Resolving the Biological Heterogeneity of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and BL (BCL-U) Using Quantitative Profiles of Oncogenic Signaling Networks
4441 - Prediction and Optimization of the Therapeutic Effect of mTOR Inhibitors in Aggressive B-Cell Lymphomas
Xue, E.
4362 - Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults
Xue, F.
555 - Two Novel Knock-in and Knock-out of Setd2 Alleles Cooperate with Mll-Af9 Knock-in Allele to Accelerate Leukemia Development
Xue, F.
3480 - Lower Dosages of Intravenous Immunoglobulin (IVIg) in Treating Immune Thrombocytopenia with Long-Term Follow-up of Three Years
Xue, L.
832 - The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
Xue, S.
1943 - Effect of Transfusion of the Third Party Umbilical Cord Blood on Haplo-Identical Hematopoietic Stem Cell Transplantation
Xue, Y.
1607 - Survival and Prognosis of Chinese Patients with Post-Polycythemia Vera Myelofibrosis
Xuefei, J.
2127 - Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy
Xuelin, H.
2943 - Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy
3775 - Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z